Skip to main content
Skip to main content
Go to homepage

REN001 in patients with Primary Mitochondrial Myopathy

Safety and Efficacy of REN001 in patients with Primary Mitochondrial Myopathy

Description:

Please view complete study details here.

Interested in participating?
We are currently recruiting
Study Sponsor:

Reneo Pharma Ltd

Full IRB Study Title:
A double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with RNE001 in patients with primary mitochondrial myopathy
IRB Study ID:
1737950
If you are interested in this study or have questions about your child's eligibility, please contact:

Hilary Tonni; htonni@akronchildrens.org; 220-543-4734

Lead Investigator
Bruce H. Cohen, MD, FAAN

Director, NeuroDevelopmental Science Center; Interim Vice President and Medical Director, Rebecca D. Considine Research Institute; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center